Atso Pharma opened the Preventix House laboratory, the only one that offers cervical cancer screening through a blood test.
In order to contribute to the timely detection of cervical cancer, the Mexican company Atso Pharma, through its holding Timser, opened the Preventix House laboratory, the only one that offers the detection test for this type of cancer through a blood test, similar to the one applied to men to detect prostate antigen.
Mercedes Gutiérrez Smith, director of Atso Pharma, pointed out that this is a great advance, since for the last 100 years, the technology for detecting this type of cancer had not changed and represented a risk, since cervical cancer is one of the most difficult carcinomas to detect.
Preventix is a general screening method for women that detects precancerous lesions and cancer with a blood sample with 90 percent effectiveness.
With the «Let’s send cancer down a tube» campaign, the Mexican company aims to contribute to the detection of women who are at risk of developing precancerous lesions and cervical cancer, by taking one more tube of blood in routine examinations at any laboratory where women arrive.
The objective is that more at-risk women reach medical consultation in a timely and effective manner and that health budgets can be applied to those who really need it.
Mercedes Gutiérrez Smith pointed out that this malignancy is the second leading cause of cancer death among women and is 95 percent preventable if detected early.
«Cervical cancer is the fourth most frequent type of cancer among women worldwide, with an estimated incidence of 604 thousand new cases and 342 thousand deaths in 2020. In this sense, the highest incidence of new cases and deaths from this disease at a global level was in low- and middle-income countries, with 90 percent of the total number of cases worldwide,» commented Mercedes Gutiérrez Smith.
With the Preventix House laboratory, Atso Pharma offers a solution in which blood can be used to diagnose precancerous lesions and cervical cancer with up to 90 percent accuracy through the detection of patented biomarkers.
With Preventix biomarkers, Mercedes Gutierrez noted that three times more population can be reached thanks to its technology. «A cancer not detected in time has a cost of two million pesos per woman for the health system. With this budget, thousands of women could be screened for a deadly disease and thus save many lives and contribute to the generation of a very positive social impact,» he added.
«This project is for our daughters, for the mothers who are no longer with us and for all of us women who have been close to cancer,» the Atso Pharma director reflected.
Finally, the director of Atso Pharma mentioned that Timser offers a comprehensive system for the collection, treatment of the sample and reporting of results in a timely manner and called on those interested in Preventix House services to visit their instagram account, https://www.instagram.com/preventix/ and use the page https://www.holapreventix.com/ to make an appointment for your test.
